

ImmuPharma "looking forward with quiet confidence" to FDA response



DIGITAL ASSET DIRECT BY IMMUPHARMA PLC

London, UK | May 24, 2023 11:08 AM Eastern Daylight Time



ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy visited Thomas Warner at Proactive's London studio to talk about the latest news on the specialty biopharmaceutical company's p140 platform. Immupharma recently announced that the US Food and Drug Administration (FDA) has endorsed the company's proposal for a late-stage clinical trial for the treatment of chronic idiopathic demyelinating polyneuropathy (CIDP), a rare neurological disorder.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Tags

BIO-TECH

IMMUPHARMA

PHARMACEUTICAL

FDA

PROACTIVE

INVEST

STOCK